Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Cannabis with high cannabidiol content is associated with fewer psychotic experiences.

Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP.

Schizophr Res. 2011 Aug;130(1-3):216-21. doi: 10.1016/j.schres.2011.04.017. Epub 2011 May 17.

2.

Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15.

Niesink RJ, Rigter S, Koeter MW, Brunt TM.

Addiction. 2015 Dec;110(12):1941-50. doi: 10.1111/add.13082. Epub 2015 Sep 18.

PMID:
26234170
3.
4.

Cannabis use and subclinical positive psychotic experiences in early adolescence: findings from a Dutch survey.

van Gastel WA, Wigman JT, Monshouwer K, Kahn RS, van Os J, Boks MP, Vollebergh WA.

Addiction. 2012 Feb;107(2):381-7. doi: 10.1111/j.1360-0443.2011.03626.x. Epub 2011 Nov 1.

PMID:
21851445
5.

Change in cannabis use in the general population: a longitudinal study on the impact on psychotic experiences.

van Gastel WA, Vreeker A, Schubart CD, MacCabe JH, Kahn RS, Boks MP.

Schizophr Res. 2014 Aug;157(1-3):266-70. doi: 10.1016/j.schres.2014.04.023. Epub 2014 Jun 12.

PMID:
24930951
6.

Cannabinoids and metabolites in expectorated oral fluid after 8 days of controlled around-the-clock oral THC administration.

Milman G, Barnes AJ, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA.

Anal Bioanal Chem. 2011 Aug;401(2):599-607. doi: 10.1007/s00216-011-5066-4. Epub 2011 Jun 3.

7.

Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study.

van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf DJ, van den Brink W, van Laar M.

Addiction. 2014 Jul;109(7):1101-9. doi: 10.1111/add.12508. Epub 2014 Mar 17.

PMID:
24628797
8.

Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.

Lee D, Milman G, Barnes AJ, Goodwin RS, Hirvonen J, Huestis MA.

Clin Chem. 2011 Aug;57(8):1127-36. doi: 10.1373/clinchem.2011.164822. Epub 2011 Jun 15.

9.

Medical use of cannabis. Cannabidiol: a new light for schizophrenia?

Deiana S.

Drug Test Anal. 2013 Jan;5(1):46-51. doi: 10.1002/dta.1425. Epub 2012 Oct 25.

PMID:
23109356
10.

Cannabis use at a young age is associated with psychotic experiences.

Schubart CD, van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA, Sommer IE, Kahn RS, Boks MP.

Psychol Med. 2011 Jun;41(6):1301-10. doi: 10.1017/S003329171000187X. Epub 2010 Oct 7.

PMID:
20925969
11.

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].

Morgan CJ, Schafer G, Freeman TP, Curran HV.

Br J Psychiatry. 2010 Oct;197(4):285-90. doi: 10.1192/bjp.bp.110.077503. Erratum in: Br J Psychiatry. 2010 Nov;197:416.

12.

Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology.

Potter DJ, Clark P, Brown MB.

J Forensic Sci. 2008 Jan;53(1):90-4. doi: 10.1111/j.1556-4029.2007.00603.x.

PMID:
18279244
13.

Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.

Morgan CJ, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, Curran HV.

Psychol Med. 2012 Feb;42(2):391-400. doi: 10.1017/S0033291711001322. Epub 2011 Jul 29.

PMID:
21798112
14.

Psychomotor performance in relation to acute oral administration of Delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects.

Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM.

Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):284-92. doi: 10.1007/s00406-009-0868-5. Epub 2009 Feb 17.

PMID:
19224107
15.

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Morgan CJ, Freeman TP, Schafer GL, Curran HV.

Neuropsychopharmacology. 2010 Aug;35(9):1879-85. doi: 10.1038/npp.2010.58. Epub 2010 Apr 28.

16.

Early adolescent cannabis exposure and positive and negative dimensions of psychosis.

Stefanis NC, Delespaul P, Henquet C, Bakoula C, Stefanis CN, Van Os J.

Addiction. 2004 Oct;99(10):1333-41.

PMID:
15369572
17.

Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk.

Konings M, Stefanis N, Kuepper R, de Graaf R, ten Have M, van Os J, Bakoula C, Henquet C.

Psychol Med. 2012 Jan;42(1):149-59. doi: 10.1017/S0033291711000973. Epub 2011 Jun 16.

PMID:
21676285
18.

Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study.

van der Meer FJ, Velthorst E; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.

Psychol Med. 2015 Jul;45(9):1977-88. doi: 10.1017/S0033291714003092. Epub 2015 Feb 5.

PMID:
25654244
19.

Early exposure to cannabis and risk for psychosis in young adolescents in Trinidad.

Konings M, Henquet C, Maharajh HD, Hutchinson G, Van Os J.

Acta Psychiatr Scand. 2008 Sep;118(3):209-13. doi: 10.1111/j.1600-0447.2008.01202.x. Epub 2008 Apr 29.

PMID:
18452569
20.

Cannabis use and dimensions of psychosis in a nonclinical population of female subjects.

Verdoux H, Sorbara F, Gindre C, Swendsen JD, van Os J.

Schizophr Res. 2003 Jan 1;59(1):77-84.

PMID:
12413646

Supplemental Content

Support Center